Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles & Cell-Free RNAs 2023

Extracellular Vesicles & Cell-Free RNAs 2023 Agenda

Co-Located Conference Agendas

Extracellular Vesicles & Cell-Free RNAs 2023 | Lab-on-a-Chip & Microfluidics World Congress 2023 | Materials & Tools for Developing POC & Rapid Dx 2023 | 

Print Agenda

Tuesday, 28 November 2023

Please View Programming Details of November 28, 2023 on Lab-on-a-Chip Agenda

Wednesday, 29 November 2023

Exhibit Hall Opens at 08:00 - Coffee, Tea and Pastries Served in the Exhibit Hall

Main Conference Programming Starts at 08:50


Michael GranerTerry MorganConference Chair

Welcome and Introduction by Conference Co-Chairs: Professor Morgan and Professor Graner -- Ballroom B
Michael Graner, Professor, Dept of Neurosurgery, University of Colorado Anschutz School of Medicine
Terry Morgan, Professor of Pathology and Laboratory Medicine, Oregon Health and Science University, United States of America

Session Title: State of the Extracellular Vesicles Field, circa 2023


Shannon StottKeynote Presentation

Immune-Associated Extracellular Vesicles in Blood
Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School, United States of America


Leyla EsfandiariKeynote Presentation

Electrokinetic-based Microchip for Purification and Characterization of Small Extracellular Vesicles
Leyla Esfandiari, Associate Professor of Biomedical Engineering, University of Cincinnati, United States of America

Small extracellular vesicles (sEVs) are lipid-bilayer delimited particles that are naturally secreted by all cells and have emerged as valuable biomarkers for a wide range of diseases. Efficient isolation of sEVs while maintaining yield and purity is crucial to harvest their potential in diagnostic, prognostic, and therapeutic applications. However, because of the complex nature of samples and the heterogeneous physicochemical properties of EVs, their accurate isolation and characterization from body fluids raises significant challenges in clinical settings. We have developed and patented a simple, yet powerful electrokinetic-based microchip capable of rapid and label-free purification of sEVs from body fluids by applying a significantly low electric field. The device also tailored with a sensing module to further characterize sEVs based on their dielectric properties by measuring their impedance. Thus, the microchip has significant potential to serve as a bioanalytical tool for liquid biopsy.


Jennifer JonesKeynote Presentation

Extracellular Biology and Liquid Biopsies: What is Next?
Jennifer Jones, NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, United States of America


Mid-Morning Coffee Break and Networking in the Exhibit Hall


Brian EliceiriKeynote Presentation

Mechanisms of Extracellular Vesicle Biogenesis that Regulate Wound Healing
Brian Eliceiri, Professor, UC San Diego, United States of America

Small extracellular vesicles (EVs) are important mediators of intercellular signaling that carry biologically active protein payloads relevant in wound healing.  However, whether EVs are analyzed from wound fluid or other biological fluids, EVs are heterogenous, reflecting in part the release of EVs from different cell types.  To address the central question of EV heterogeneity in parallel with the unmet need for in vivo sources of EVs with low platelet contamination, we have developed a macroporous scaffold for the subcutaneous implantation and subsequent collection of EVs that is applicable for the study of EV activity in any defined mouse model. Using polyvinylalcohol (PVA) sponges as the scaffold, we first show that the rapid infiltration of immune cells of hematopoietic origin is accompanied a substantial and heterogenous population of EVs. Second, we show how single vesicle flow cytometry (vFC) addresses the heterogeneity challenge by quantifying the expression of surface markers that map to specific subpopulations of EVs relevant to cellular origin.  Third, we show how in vitro two-dimensional cell culture, although common, introduces significant bias in EV release that is addressed with the PVA scaffold in vivo model. Together these studies, define a novel model establishing the biochemical basis and biological activity of EVs in the biology of wound healing.


Larry ChamleyKeynote Presentation

Placental Extracellular Vesicles; Regulators of Maternal Physiology
Larry Chamley, Professor and Head of Department of Obstetrics and Gynaecology, University of Auckland, New Zealand

The human placenta produces vast quantities of extracellular vesicles into the maternal blood continuously during pregnancy. Biodistribution studies indicate that the majority of these EVs are taken up from the maternal blood rapidly in the lungs, liver kidneys and spleen. Functional studies demonstrate that normotensive placental EVs can protect against the development of hypertension long-term while EVs from pregnancies complicated by preeclampsia a hypertensive disease of pregnancy activate the maternal endothelium and induce a pro-constrictive phenotype in resistance arteries.  These functional studies suggest that the protein and/or regulatory RNA cargos of placental EVs have a long-lasting regulatory effect on  the maternal cardiovascular system.


Terry MorganConference Chair

Everything We Think We Know About Extracellular Vesicle Cargo is Wrong
Terry Morgan, Professor of Pathology and Laboratory Medicine, Oregon Health and Science University, United States of America

Extracellular vesicles (EVs) comprise a range of submicron particles, including small EVs (exosomes ~75-150 nm) derived from endosomal biogenesis, larger microvesicles (< 1um) that bud directly from the cell membrane, and fragments of cells undergoing necrosis and/or apoptosis. These lipid encapsulated EVs contain surface cell-specific protein markers and a variety of RNAs that provide insights into their source and potential function (e.g. regulating angiogenesis and immune microenvironments).  Methods like density gradient ultracentrifugation followed by size-exclusion chromatography (SEC) provide a heterogeneous mixture of EVs from a variety of cell sources, and in a variety of sizes. Affinity capture lacks size-specificity, which is important because larger microvesicles are thought to have entirely different contents and biological functions than small EVs (exosomes). These methodological shortcomings have limited adequate EV profiling and characterization.  To address this need, the Morgan laboratory uses multiplex nanoscale fluorescent activated cytometric sorting (nanoFACS) with 40nm resolution to image, count, and isolate cell- and size-specific EVs. Importantly, this next generation approach provides highly efficient flow sorting of multiplex-labeled EVs at the 0.3 nanoliter droplet scale (5x better than commercially available FACS machines using our custom made sorting nozzle and EV-specific protocol).  We have completed validation studies characterizing flow sorted placental EVs according to guidelines put forth by the International Society of Extracellular Vesicles (ISEV), including nanoparticle tracking analysis, CryoEM, ELISA, and microRNA content within small EVs compared with flow sorted 100nm liposomes spiked into the same plasma samples. Spiked in liposomes are an important negative control for background contamination inherent in any EV isolation method and novel to our EV isolation approach.


Networking Luncheon in the Exhibit Hall -- Network with Exhibitors, View Posters and Engage with Colleagues

Session Title: Technologies Driving the Extracellular Vesicles Field Forward, circa 2023


Daniel ChiuKeynote Presentation

Digital Flow Cytometry for the High-Throughput Multiplexed Analysis of Single Extracellular Vesicles and Particles
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

Extracellular vesicles and particles (EVPs) play a central role in liquid biopsy, intercellular communication, and disease transmission and progression, and are emerging therapeutic tools. To better understand the biology of EVPs and fully unlock their diagnostic and therapeutic potential, it is critical to access quantitative information regarding their concentration, size, and biological heterogeneities. To meet this need, we have developed a single-molecule sensitive flow platform, which uses a high-throughput 12-channel flow analyzer that detects each and every fluorescent molecule flowing through a microfluidic channel, and enables multiparameter characterization of EVPs, including single-EVP phenotyping, sizing, and the absolute quantitation of EVP concentrations and biomarker copy numbers.  This new flow technology should have a broad range of applications, from analysis of single EVPs such as exosomes or RNA-binding proteins to characterization of therapeutic lipid nanoparticles, viruses, and proteins; it also provides absolute quantitation of non-EVP samples such as dyes, beads, and Ab-dye conjugates.


Particle Metrix GmbH and CEO, Particle Metrix Inc., USAParticle Metrix GmbH Technolology Spotlight Presentation
Sven Rudolf Kreutel, Chief Executive Officer, Particle Metrix GmbH and CEO, Particle Metrix Inc., USA


BD Biosciences Technology Spotlight Presentation


Mid-Afternoon Coffee Break and Networking in the Exhibit Hall


Steve SoperKeynote Presentation

Screening Tests using Micro- and Nanofluidics for Early Detection of Ovarian Cancer with Extracellular Vesicles Serving as the Input
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas, United States of America

We are developing screening tests consisting of novel hardware, biomarkers, and assays to service a number of diseases, including the early detection of cancer and viral infections. The commonality in these tests is that they consist of microfluidic devices made from plastics via injection molding. Thus, our tests can be mass produced at low-cost to facilitate bench-to-bedside transition and point-of-care testing (PoCT) for large scale population screening. The assays are based on the use of liquid biopsy markers as the input, which can be secured in a non- to minimally-invasive manner appropriate for screening. Recently we have focused on developing plastic nanofluidic devices, which provides unique opportunities for single-entity analyses – these devices can also be injection molded. In this presentation, we will discuss the evolution of our fabrication efforts of plastic-based microfluidic and nanofluidic devices as well as their surface modification to make devices appropriate for screening using extracellular vesicles (EVs) as the input. Then, we will discuss the application of the device and the associated assay for selection of rare liquid biopsy targets (EVs) from clinical samples to serve as screening tests. The specific application we will discuss is the analysis of EVs for the early detection of ovarian cancer. Ovarian cancer is the 5th most deadly cancer for women in the US and has a 46.2% 5-y survival rate. Unfortunately, ~85% of cases are diagnosed at a late stage of disease providing pore outcomes for these patients. Therefore, new strategies for early detection are required. The screening test we are developing consists of a microfluidic chip for EV affinity selection, which consists of a high density array of pillars surface-decorated with antibodies to efficiently select EVs followed by the label-free enumeration to determine elevated levels of EVs in the plasma of patients suspected of having ovarian cancer. Unique EV-associated surface proteins were discovered for selection of ovarian cancer EV specifically for the early detection of disease. The selected EVs were counted using a nano-Coulter Counter chip (nCC), which consisted of in-plane nanopores. Both steps of the screening test described here were carried out using a microfluidic and nanofluidic chips integrated to a control board for automating sample processing with results produced within 20 min.


SpectradyneAccurate Nanoparticle Size, Concentration, and Payload with Spectradyne’s ARC Particle Analyzer
Jean-Luc Fraikin, CEO, Spectradyne

Spectradyne’s ARC particle analyzer uses a unique combination of electrical and optical measurement techniques to accurately measure the size, concentration, and internal and external payload of nanoparticles as small as 50 nm in diameter.  Learn how scientists are using the ARC to quantify single-particle encapsulation efficiency for LNPs and characterize subpopulations of extracellular vesicles based on surface marker expression profiles.


NanoFCMCombining Flow Cytometry and Particle Analysis to Meet the Challenges of EV Characterization
Michael Jacobs, Applications Scientist, NanoFCM

NanoFCM aims to bring reliable and quantitative measurements to the nanoscale to support the emergence of new classes of diagnostics and therapeutics. This presentation will focus on illustrating how our NanoAnalyzer platform is able to interrogate EVs one by one, utilizing high resolution side scatter detection and fluorescence to identify molecules of interest associated with individual particles and sub-populations. Various examples will be presented which demonstrate how this technology can be applied for gathering physical and phenotypic information of EVs.


The University of KansasLiquid Biopsy Core (LBC) - Enabling Tools for the Isolation of Liquid Biopsy Markers and Their Molecular Analysis
Malgorzata Witek, Associate Research Professor, The University of Kansas

Liquid biopsies are minimally invasive tests that can be performed frequently, providing “real-time” information on disease status to improve patient outcome. Analyzing different biomarkers present in liquid biopsies, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), requires enrichment to select the low abundant disease-associated markers from clinical samples. The LBC provides a diverse range of technologies that are directed at both enriching liquid biopsy markers and their downstream molecular analysis. The LBC uses a combination of microfluidics with full process automation for enriching the full complement of liquid biopsy markers with exquisite analytical figures-of-merit. As examples of utility of LBC technologies, we will present clinical data on identifying the molecular subtypes of breast cancer using EV’s mRNA and monitoring response to therapy in pancreatic cancer via CTCs.


Dielectrophoresis Based Collection of Extra Cellular Vesicles and On Chip Analysis of Nucleic Acid Payload
Stuart Ibsen, Assistant Professor, The Knight Cancer Institute’s Cancer Early Detection Advanced Research Center (CEDAR), Oregon Health and Science University, United States of America

Differentiating patients with pancreatic cancer (PDAC) from patients with precancerous intraductal papillary mucinous neoplasms (IPMN) and pancreatitis is a challenge using traditional blood-based biomarkers like CA 19-9. Extracellular vesicle (EV) nanoparticles are a valuable source of cancer-derived biomarkers that are released by tumors into circulation throughout their development. These particles include extracellular vesicles, organelle fragments, and cell free DNA (cf-DNA) nanoparticles. However, it is a challenge to use these nanoparticles for clinical diagnostic applications due the difficulty of recovering them from plasma for analysis. We address this challenge through the use of high conductance dielectrophoresis (DEP) to simultaneously recover different nanoparticle types from a single undiluted plasma sample in a quick and easy microfluidic chip format. This method takes advantage of the difference in the dielectric properties between the nanoparticles and the surrounding plasma to create a force that pulls nanoparticles down to an electrode array. The particles are held with enough force to remove the bulk plasma using a fluidic wash. This can simultaneously collect both EVs and cf-DNA nanoparticles around the edges of the electrodes used to generate the DEP force. The combination of EV biomarkers (Glypican-1) and the level of cf-DNA nanoparticles can be used to successfully differentiate PDAC patients from patients with benign pancreatic diseases using a blinded cohort study design. This can also differentiate between PDAC patients and patients with IPMN making this study among the first that we are aware of developing a multiomic threshold that can distinguish between PDAC and IPMN lesions. This is clinically important because IPMNs are a major source of false positives for multiomic biology-based screening. This multiomic biomarker panel had a sensitivity of 0.92, a specificity of 0.88, and an AUC of 0.80 in differentiating between PDAC and benign pancreatic diseases, which is comparable to the traditional invasive endoscopic ultrasound-guided fine needle aspiration (EUS/FNA) diagnostic procedure (AUC 0.79). This new dielectrophoresis-based technique shows multiple types of cancer-derived nanoparticles can be quickly and easily recovered from a single plasma sample and that their associated biomarkers are promising for future use in clinical diagnostics.


Networking Reception with Beer and Wine in the Exhibit Hall


Close of Conference Day

Thursday, 30 November 2023


Morning Coffee, Pastries and Networking in the Exhibit Hall


Kinetic River CorpUltrasensitive EV Detection by Flow Cytometry
Giacomo Vacca, President & CEO, Kinetic River Corp

The Delaware Flow NanoCytometer is a particle analyzer designed for high scattering and fluorescence sensitivity. It can detect particles as small as 28 nm, it resolves size differences as small as 22 nm, and it can also measure cells. With up to 6 channels of fluorescence and the high throughput typical of flow cytometry, it offers EV measurement capabilities found nowhere else.


Shuichi TakayamaKeynote Presentation

Immiscible Aqueous Droplets for Biosensing, Wound Healing Models, and Exosome Manipulation
Shuichi Takayama, Professor, Georgia Research Alliance Eminent Scholar, and Price Gilbert, Jr. Chair in Regenerative Engineering and Medicine Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University School of Medicine, United States of America

Liquid-liquid phase separation (LLPS) occurs physiologically inside each of our cells. LLPS can also be observed with various polymer systems such as poly(ethylene glycol) PEG, dextran (DEX) where immiscible aqueous two-phase systems (ATPS) are formed. This talk will describe ATPS fundamentals as well as application of ATPSs in cellular biopatterning including for wound healing studies, exosome isolation, and molecular biosensing.


CD47 Functions in Extracellular Vesicle RNA Cargo Loading and Extracellular Signaling in Cancer and Immune Cells
Sukhbir Kaur, Staff Scientist, National Cancer Institute, National Institutes of Health, United States of America


Mid-Morning Coffee Break and Networking in the Exhibit Hall


Beckman Coulter Life SciencesFlexible Solutions for Extracellular Vesicle Analysis
Jason Lowery, Regional Marketing Development Manager, Beckman Coulter Life Sciences

During this presentation, we will discuss some of the current challenges with Flow Cytometry for Extracellular Vesicle (EV) analysis and what it would take to make a purpose-built analyzer. With over 88 years of experience, Beckman Coulter Life Sciences is dedicated to driving innovation in research through improvements in EV analysis. We offer a number of products and solutions, including the CytoFLEX Flow Cytometer and the CytoFLEX SRT benchtop cell sorter, providing the sensitivity and performance you need in an easy-to-use system, for your EV research solutions.


Cytek BioSciencesExpanding Capabilities for Small Particle Analysis Using Imaging Flow Cytometry and Full Spectral Flow Cytometry
Stephanie Brunelle, Senior Product Manager, Cytek BioSciences

In this presentation, we will discuss how to expand analysis options to study small particles and extracellular vesicles (EVs) using Cytek’s solutions, including the Cytek® Amnis® ImageStream®, Cytek® Aurora™, and Cytek® Northern Lights™ systems.  Research in microbiology, virology, nanoparticles, and EVs has grown tremendously over the past few years. Small bacteria, viral particles, nanoparticles, and small EVs, such as exosomes (less than 150 nm in diameter), are all on the subcellular scale. Detection, quantification, and characterization of small objects in a reproducible and reliable manner is challenging due to their small size and interference with debris. We will demonstrate the capabilities of the Cytek® systems for small particle applications. The Cytek® Amnis® ImageStream®X Mk II system, which combines the quantitative power of flow cytometry with microscopy in one system, has a “High Gain” mode to increase the sensitivity for small particle detection by adjusting the CCD-camera to a higher gain setting, thus increasing the signal obtained from the small particles while minimizing the noise.  We will present data from analyzing recombinant EVs expressing green fluorescent protein (GFP) on the ImageStream® system using “High Gain” mode.  Data from EV size measurements, GFP expression, and tetraspanin expression in calibrated units will be presented. The Cytek® Aurora™ and Northern Lights™ full spectrum flow cytometers can be upgraded with the Enhanced Small Particle™ (ESP™) detection option. With the blue SSC detector and new violet SSC collection optics that enhance small particle sensitivity and resolution, both systems allow full SSC dynamic range to detect large cells and subcellular EVs. We will show bead and EV data from our high-sensitivity detectors, flat-top beam profiling, and low-noise electronics on the Cytek® Aurora™ system and how they can be combined for small particle detection. The data presented illustrates how the various tools and technologies available from Cytek for EV analysis provide robust and reproducible results for advancing discovery in this field.


Danilo TagleKeynote Presentation

NCATS Program on Exosome Therapeutics for Regenerative Medicine (ExTReMe)
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Extracellular vesicles (EVs), membrane-bound particles containing a variety of RNA types, DNA, proteins and other macromolecules, are now appreciated as an important means of communication between cells and tissues, both in normal cellular physiology and as a potential indicator of cellular stress and other environmental exposures and early disease pathogenesis. EVs have pleiotropic actions in physiological and pathological conditions.  EVs are commonly heterogeneous in size, ranging from 20 to 1,000 nm in diameter depending on their origin and mechanism of release, direct shedding or budding from the plasma membrane. Exosomes are vesicles with a diameter of 20–100 nm formed by the inward budding of endosomal membranes to form large multivesicular bodies (MVBs) and released extracellularly when MVBs fuse with the plasma membrane.  Exosomes have recently been studied for their potential use in therapy as a 1) targeted and non-immunogenic delivery system for drugs or biological molecules, and 2) in the maintenance of tissue homeostasis and their contribution to tissue repair and regeneration. This presentation will summarize NIH-funded activities in exploring the therapeutic applications of exosomes along with application of new experimental models, including organ-on-chip (OOC) systems and in vitro approaches to extend findings.


Andrea RaymondKeynote Presentation

Opiates and HIV Alter Exosomal EV microRNA Cargo
Andrea Raymond, Associate Professor, Herbert Wertheim College of Medicine, Florida International University, United States of America

Opiate abuse increases the risk of HIV transmission and exacerbates Human Immunodeficiency Virus (HIV) neuropathology by increasing inflammation and modulating immune cell function. However, the exact mechanism(S) for these observations is unclear Exosomal EVs(xEV) contain miRNAs that are differentially expressed due to HIV infection or opiate abuse. Here we developed a preliminary exosomal-miRNA biomarker profile of HIV-infected PBMCs in the context of opiate use.  Functional studies show that xEVs derived from peripheral blood mononuclear cells(PBMCs) exposed to opiates reduced viability and function of neurons. Using Nanostring microRNA arrays we show that morphine and HIV induced differential miRNA expression in PBMC-derived exosomes, potentially identifying a biomarker of opiate use disorder(OUD) and  mechanisms of action or novel therapeutic targets involved in OUD, neuropathology, TNF-a signaling pathway, NF-kB signaling pathway, autophagy, and apoptosis in context of HIV infection.


Kendall Van Keuren-JensenKeynote Presentation

Extracellular RNAs Associated with Neurodegenerative Disease and Injury
Kendall Van Keuren-Jensen, Professor and Deputy Director, Translational Genomics Research Institute, United States of America


Networking Buffet Lunch in the Exhibit Hall -- Networking with Colleagues, Engage with Exhibitors and View Posters

Add to Calendar ▼2023-11-28 00:00:002023-11-30 00:00:00Europe/LondonExtracellular Vesicles and Cell-Free RNAs 2023Extracellular Vesicles and Cell-Free RNAs 2023 in Laguna Hills, CaliforniaLaguna Hills,